MedWatch

Eargo weathers the storm – stays listed on US exchange

Hearing aid manufacturer Eargo has handed in its first report for 2022, which had reportedly been delayed due to a now-settled fraud case, and has been allowed to stay listed on the exchange in New York.

Christian Gormsen, adm. direktør i Eargo | Photo: Eargo / PR

The list of firms publicly traded firm in the US will continue to include hearing aid manufacturer Eargo.

This wasn’t a given – the company had received not one but two warnings threatening delisting from Nasdaq Stock Market in New York because the US Securities and Exchange Commission (SEC) had not received several consecutive financial reports from the firm.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs